MNKD - MannKind Corp logo

MannKind Corp

MNKD
Rev 3936xtop 1%20Y
Compare MNKD Hold

MannKind Corporation develops and commercializes inhaled therapeutic products for chronic diseases. Its offerings include Afrezza inhalation powder for diabetes, the V-Go insulin delivery device, and Tyvaso DPI for pulmonary hypertension.

โš•๏ธ Healthcare NASDAQ Listed 2004 $ USD
$1,000 invested 20 years ago โ†’$35today

Score Overview

1 Year
Score
Net Growth-7x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth12.80%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.9
Net Growth46.11%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth421.77%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-134.71%
Net Trend40%
Net Income Consistency
Rev Growth125.24%
Rev Trend90%
Revenue Consistency
20 Years
Score3.9
Net Growth81.08%
Net Trend40%
Net Income Consistency
Rev Growth3936x
Rev Trend67%
Revenue Consistency
All Time
Scoreโ€”
Net Growth42.61%
Net Trend36%
Net Income Consistency
Rev Growthโ€”
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where MannKind Corp has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • MNKD

2012: 76.8% ยท 2019: 71.8% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 3.34โ€”
1 Year2025-09-29
$ 5.39-38.03%
5 Years2021-09-29
$ 4.48-25.45%
10 Years2016-09-29
$ 3.0011.33%
20 Years2006-09-29
$ 95.00-96.48%
All Time2004-07-28
$ 70.40-95.26%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 393M-$ 43M$ 111M
2025$ 348M$ 5M$ 171M
2024$ 285M$ 27M$ 197M
2023$ 198M-$ 11M$ 295M
2022$ 99M-$ 87M$ 170M
2021$ 75M-$ 80M$ 204M
2020$ 65M-$ 57M$ 67M
2019$ 63M-$ 51M$ 49M
2018$ 27M-$ 86M$ 71M
2017$ 11M-$ 117M$ 43M
2016$ 174M$ 125M$ 22M
2015$ 0.00-$ 368M$ 59M
2014$ 0.00-$ 198M$ 120M
2013$ 3M-$ 191M$ 70M
2012$ 35K-$ 169M$ 61M
2011$ 50K-$ 160M$ 3M
2010$ 93K-$ 170M$ 70M
2009-$ 220M$ 32M
2008$ 20K-$ 303M$ 46M
2007$ 10K-$ 293M$ 368M
2006$ 100K-$ 230M$ 436M
2005-$ 114M$ 145M
IPO2004-$ 75M$ 90M
MNKD - MannKind Corp logo

MannKind Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 65M to $ 348M and net income went from -$ 57M to $ 5M. Revenue increased in every one of those 5 years; net income in 2.

Between 2005 and 2025, net income went from -$ 114M to $ 5M. Revenue increased in 13 of those 20 years; net income in 8.

MannKind Corp currently holds a 20-year HDB Score of 3.9 out of 10. How the HDB Score is calculated.

Membership

Continue MNKDโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies